Moderna Stock Surges 4.44 as $300M Trading Volume Ranks 378th FDA Approval Bolsters Vaccine Confidence

, , . The stock’s performance was influenced by developments in its vaccine pipeline and regulatory updates.

The U.S. Food and Drug Administration (FDA) approved Moderna’s supplemental Biologics License Applications (sBLA) for the 2025-2026 formulations of Spikevax and mNEXSPIKE, targeting the SARS-CoV-2 LP.8.1 variant. This regulatory milestone reinforced confidence in the company’s ability to adapt its vaccine portfolio to emerging viral strains, potentially bolstering its market position in the evolving pandemic landscape.

. While no immediate financial details were disclosed, , particularly as demand for seasonal and pandemic preparedness vaccines persists.

To make sure I structure the back-test exactly as you intend, could you confirm a few details? 1. Market universe – should we use all U.S. listed stocks, another region, or a specific index universe (e.g., S&P 1500 constituents)? 2. “Daily trading volume” – do you mean share volume or dollar volume? 3. , ? 4. ? ? 5. , ? Once I have these details, I can set up the retrieval plan and run the back-test.